PRAX vs RYTM
PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | PRAX | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $315.80 | $105.74 | |
| Market cap as of 2026-08-01 | $8.8B | $7.2B | |
| PEG as of 2026-08-01 | -0.92 | -2.94 | RYTM lower |
| Net margin as of 2026-08-01 | -2137.5% | -93.3% | RYTM higher |
| Gross margin as of 2026-08-01 | n/a | +89.4% | |
| Operating margin as of 2026-08-01 | -2340.3% | -90.9% | RYTM higher |
| ROE as of 2026-08-01 | -43.0% | -86.5% | PRAX higher |
| ROA as of 2026-08-01 | -40.2% | -45.0% | PRAX higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.46 | PRAX lower |
| Revenue growth (YoY) as of 2026-08-01 | n/a | +58.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +100.2% | |
| Beta as of 2026-08-01 | 2.81 | 1.98 | |
| 1-year return as of 2026-07-27 close | +433.3% | +24.9% | PRAX higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.